The government expressed the will to encourage pharmaceutical companies to invest in research and development (R&D) and secure the momentum of developing two homegrown blockbuster drugs through the reform of the drug pricing system to reflect innovative value.

Above all, the government has made it clear that it will strengthen the sustainability of national health insurance finances by reducing the proportion of pharmaceutical expenses, and at the same time, investing the funds generated by trimming the insurance drug prices of drugs that violate the purpose of selective benefits into innovative new drugs and essential drugs.

In particular, the government said it had devised the reform of t